Long-Acting Injection Better for PrEP in Men, Gender-Diverse Groups

Source link : https://www.yourblogdomain.com/2024/11/27/long-acting-injection-better-for-prep-in-men-gender-diverse-groups/

Source link : https://www.newshealth.biz/health-news/long-acting-injection-better-for-prep-in-men-gender-diverse-groups/ Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE 2 trial. Injections every 26 weeks cut the rate of HIV infections by a relative 89% compared with daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF, Truvada), with […]

Author : yourblogdomain

Publish date : 2024-11-27 22:42:35

Copyright for syndicated content belongs to the linked Source.